5 Popular Penny Stocks on Robinhood to Buy

4. SELLAS Life Sciences Group Inc. (NASDAQ:SLS)

Average Daily Trading Volume: 9.32 million shares

Stock Price: $5.00

Stock Upside: 100.20%

Number of Hedge Fund Holding: 6

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026.

SLS009, alternatively known as tambiciclib, is a selective CDK9 inhibitor. Put simply, this is a treatment designed to stop a specific “worker” protein in human cells called CDK9. SELLAS said it will present the data in a poster session. That is, instead of giving a formal speech on the stage at the San Diego Convention Center, the company will only display a printed poster.

The poster, titled “Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell lines,” centers on the drug’s mechanism of action in acute myeloid leukemia, or AML, the company said in a press release statement. According to preclinical data, said SELLAS, SLS009 retained its activity in AML models carrying ASXL1 and TP53 mutations. To the company’s experts, this behavior underscores the drug’s potential to address patient populations that currently have very limited treatment options.

Earlier on March 12, SELLAS enrolled its first patient in a newly diagnosed, first-line AML trial of SLS009 in combination with venetoclax and azacitidine. This came after the FDA guidance that recommended this expansion after the drug met all endpoints in its completed Phase 2 trial in relapsed/refractory (r/r) AML. In the trial, the drug exceeded the pre-specified 20% overall response rate threshold with favorable safety and tolerability.

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is a clinical-stage biopharmaceutical company that develops cancer immunotherapies. Its lead product candidate is galinpepimut-S, a peptide-based immunotherapy designed to treat hematologic cancers and solid tumors.